Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor.

Published bySudomo Sutedja Modified over 5 years ago

Similar presentations

Presentation on theme: "Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor."— Presentation transcript:

1 Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications.
Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. PRs exist as either A (97 kDa) or B (120 kDa) translated from the same gene by the use of alternate promoters. Each isoform contains a C-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) and at least two transcriptional activation function (AF) domains. AF1 and AF2 are located within the aminoterminal domain (ATD) and the LBD, respectively. PRB contains an additional AF (AF3) within the unique 164-amino acid B-upstream segment. Adapted from Lange;13 Hill KK, et al.14 Jacques Bonneterre et al. ESMO Open 2016;1:e000072 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor."

Similar presentations

Caption N-terminal domain A/B domain: ligand-independent domain AF1: Activation Function 1 DBD: DNA Binding Domain LBD: Ligand Binding Domain: ligand-dependent.

Caption N-terminal domain A/B domain: ligand-independent domain AF1: Activation Function 1 DBD: DNA Binding Domain LBD: Ligand Binding Domain: ligand-dependent.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Robert H. Oakley, PhD, John A. Cidlowski, PhD 

Robert H. Oakley, PhD, John A. Cidlowski, PhD 
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Gonadal Steroid Action

Gonadal Steroid Action
Schematic representation of main EGFR-TKIs resistance mechanisms.

Schematic representation of main EGFR-TKIs resistance mechanisms.
The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Oestrogen and progesterone action on endometrium: a translational approach to understanding endometrial receptivity  Steven L. Young  Reproductive BioMedicine.

Oestrogen and progesterone action on endometrium: a translational approach to understanding endometrial receptivity  Steven L. Young  Reproductive BioMedicine.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Similar presentations

Ads by Google